Hormonal
GLP-1 receptor agonists suppress appetite through a non-aversive neural pathway (NTS GLP1R neurons projecting to PVH) that is distinct from the nausea-inducing pathway (Area Postrema GLP1R neurons projecting to PBN/CeA), allowing for weight loss without nausea.
GLP-1 medications like semaglutide work through two separate brain pathways: one that makes you feel full without feeling sick, and another that causes nausea. You can achieve significant weight loss through the 'fullness' pathway even if you experience some nausea, but the nausea itself isn't required for the fat loss. If nausea is severe, it may indicate you are activating the nausea pathway more than the satiety pathway, and dose adjustments might help optimize the benefit-to-side-effect ratio.
This supports the idea that the nausea pathway is not necessary for effective weight loss by GLP1R-agonists-based drugs... NTS GLP1R+ neurons inhibit feeding through a non-aversive pathway involving the paraventricular hypothalamus (PVH)... unlike the area postrema GLP1R+ neurons... When both the NTS and area postrema GLP1R+ neurons are lost, GLP1R agonists-induced feeding suppression is eliminated [10].
Why this rating
Based on a review citing high-impact primary studies (Nature, Neuron) using genetic ablation and in vivo imaging in animal models.
Source
Neural pathways of nausea and roles in energy balance
Chuchu Zhang · Current Opinion in Neurobiology · 2025
DOI 10.1016/j.conb.2024.102963
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →